Chinese patent medicine for osteoporosis: a systematic review and meta-analysis

References

• Kanis JA, Melton LJ, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137–1141.
   PubMed Web of Science ®Google Scholar
• Hopkins RB, Burke N, and Von Keyserlingk C, et al. The current economic burden of illness of osteoporosis in Canada. Osteoporos Int. 2016;27:3023–3032.
   PubMed Web of Science ®Google Scholar
• Chen P, Li Z, Hu Y. Prevalence of osteoporosis in China: a meta-analysis and systematic review. BMC Public Health. 2016;16:1039.
   PubMed Web of Science ®Google Scholar
• Ensrud KE, Crandall CJ. Osteoporosis. Ann Intern Med. 2017;167:ITC17–ITC32.
   PubMed Web of Science ®Google Scholar
• Ensrud KE, Crandall CJ. Bisphosphonates for postmenopausal osteoporosis. JAMA. 2019;322:2017–2018.
   PubMed Web of Science ®Google Scholar
• Ge JR, Wang HM, Zheng HX, et al. Traditional Chinese Medicine Expert Consensus on the prevention and treatment of primary osteoporosis (2020). Chin J Osteoporosis. 2020;26. 1717–1725.
   Google Scholar
• Sun S, Mo X, Li Y, et al. Effectiveness comparisons of Chinese patent medicine on treating premature ejaculation: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e17729.
   PubMed Web of Science ®Google Scholar
• Liu Y, Li Z, Shen D, et al. Adjuvant treatment of coronary heart disease angina pectoris with Chinese patent medicine: a prospective clinical cohort study. Medicine (Baltimore). 2019;98:e16884.
   PubMed Web of Science ®Google Scholar
• Wang SJ, Yue W, Rahman K, et al. Mechanism of treatment of kidney deficiency and osteoporosis is similar by traditional Chinese medicine. Curr Pharm Des. 2016;22(3):312–320.
   PubMed Web of Science ®Google Scholar
• Lin J, Zhu J, Wang Y, et al. Chinese single herbs and active ingredients for postmenopausal osteoporosis: from preclinical evidence to action mechanism. Biosci Trends. 2017;11(5):496–506.
   PubMed Web of Science ®Google Scholar
• Zhan KJ, An YJ, Mou X. Efficacy of kidney-tonifying Chinese patent medicine on bone turnover makers in postmenopausal osteoporosis: a meta-analysis. Chin J Osteoporosis. 2019;25:202–211.
   Google Scholar
• Zhang BS, Dong KF. A meta-analysis of efficacy of two kinds of the Bushen medicine on BMD and VAS in osteoporosis patients. Clin J Chin Med. 2020;12:139–143.
   Google Scholar
• Jiang YQ, Yu GS, Tong PJ. A meta-analysis of Zuogui pills in the treatment of osteoporosis. J New Chin Med. 2019;51:52–56.
   Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
   PubMed Web of Science ®Google Scholar
• Osteoporosis Committee of Chinese Gerontology Society. Recommended diagnostic criteria for osteoporosis in China (second draft). Chin J Osteoporos. 2000;1–3.
   Google Scholar
• Osteoporosis Committee of Chinese Gerontology Society. Expert consensus on diagnostic criteria for osteoporosis in Chinese (third draft). Chin J Osteoporos. 2014;20:1007–1010.
   Google Scholar
• Chinese Medical Association. Clinical practice guidelines·Osteoporosis and bone mineral salt diseases. Beijing: People’s Medical Publishing House; 2006. p. 1–8.
   Google Scholar
• The Osteoporosis and Bone Mineral Salt Disease Branch of Chinese Medical Association. Guidelines for diagnosis and treatment in primary osteoporosis. Chin J Osteoporosis Bone Mineral Res. 2011;4:2–17.
   Google Scholar
• Liu ZH. Diagnostic criteria for primary osteoporosis in China (trial). Chin J Osteoporos. 1999: 4–6.
   Google Scholar
• Zheng XY. Guiding principle of clinical research on new drugs of traditional Chinese medicine. Beijing China; 2002. p. 349–353.
   Google Scholar
• Liu YB. Observation on effect of gusongbao capsule in treating osteoporotic spinal compression fracture. Chin J Clin Rational Drug Use. 2020;13:77–78.
   Google Scholar
• Le SH. Effect of xianling gubao capsule on postoperative recovery of senile patients with osteoporosis complicated with fracture undergoing surgical treatment. Chin J Clin Rational Drug Use. 2020;13:96–97.
   Google Scholar
• Yuan YF, Huang XS, Yang YR, et al. Study on effect of Jintiange capsule on lower limb functionin patients with primary type □ osteoporosis. Chin J Tradition Med Traumatol Orthoped. 2019;27. 24–27+31.
   Google Scholar
• Zeng M, Lu P, Yang B, et al. The efficacy of Jintiange capsule on the treatment of postmenopausal osteoporosis. Chin J Osteoporosis. 2016;22. 480–482.
   Google Scholar
• Qin Y, Qiu B, Zhu SG, et al. Clinical observation of Jintiange capsule on treating postmenopausal osteoporosis. J Qiannan Med Coll Nationalities. 2016;29. 19–23.
   Google Scholar
• He BY, Teng T, Liu BG, et al. The clinical efficacy of Jintiange capsule on the treatment of primary osteoporosis. Chin J Osteoporosis. 2015;21. 168–174.
   Google Scholar
• Cai D, Lin ZX, Huang ZH, et al. Clinical effect observation of Alendronate combined with Jintiange capsule in the treatment of postmenopausal osteoporosis. China Pharm. 2015;18:1352–1354.
   Google Scholar
• Zhao G, Xu ZL, Shao QX, et al. Confarison of livial and kidney-invigorating traditional Chinese medicine in prevention and treatment of postmenopausal osteoporosis. Chin J Osteoporosis. 2004;03. 87–89.
   Google Scholar
• Wang J, Zhang WK, Wang ZH. Qianggu capsule was used to treat 28 cases of postmenopausal osteoporosis. Herald Med. 2007;11:1325–1327.
   Google Scholar
• Ji XR. Clinical observation of Qianggu Capsule in the treatment of senile osteoporosis. Shanxi Medical J. 2006;04:341–342.
   Google Scholar
• Gu M, Guo JN. The Rhizoma Drynariae therapy for primary osteoporosis. Chin J Rehabilitation. 2004;05:297.
   Google Scholar
• Wang Y, Liu J, Hou YX, et al. Study on the safety and efficacy of Dizhongqianggu capsule in the treatment of osteoporosis. Chin J Osteoporosis. 2019;25. 1454–1457.
   Google Scholar
• Shan S, Zhou G. Clinical effect of Qianggu Capsule on primary osteoporosis. Northwest Pharmaceutical J. 2006;04:177–178.
   Google Scholar
• Niu Y. The therapeutic effect of Qing’e Wan therapy in postmenopausal women with osteoporosis. Shenzhen J Integr Traditional Chin West Med. 2012;22:101–103.
   Google Scholar
• Jin JF, and Zhang JW. Clinical efficacy and safety evaluation of Xianlinggubao capsule treatment of osteoporosis pain. Chin Arch Tradition Chin Med. 2014;32:3050–3052.
   Google Scholar
• Qin Y, Qiu B, Zhu SG. Analysis of the efficacy of Xianlinggubao capsule on the treatment of osteoporosis and its influences in the markers of bone metabolism and bone turnover. Chin J Osteoporos. 2015;21:1056–1060+1064.
   Google Scholar
• Wu YJ. Clinical effect observation of Xianlinggubao in the treatment of osteoporosis. J Clin Exp Medi. 2013;12:1494–1495.
   Google Scholar
• Zheng HQ. Clinical observation of xianlinggubao in the treatment of primary osteoporosis. J China Prescription Drug. 2016;14:83–84.
   Google Scholar
• Lin H, Yang CS. Efficacy of Xianlinggubao in the treatment of primary osteoporosis. Shenzhen J Integr Traditional Chin West Med. 2017;27:54–56.
   Google Scholar
• Xu M, Liu BX, Huang CJ, et al. Clinical observation of xianlinggubao plus alendronate on postmenopausal osteoporosis. J Liaoning Univ Traditional Chin Med. 2009;11:94–95.
   Google Scholar
• Zhang HB, Li CY. Effect of Liuwei Dihuang Pill on bone mineral density of the primary osteoporosis (kidney yin deficiency). Chin J Tradition Med Traumatol Orthoped. 2011;19:18–20.
   Google Scholar
• Guan J, Tang JF, Guo GR. Intervention of Liuwei Dihuang Pill on bone density in patients with postmenopausal osteoporosis. Chin J Inf Traditional Chin Med. 2006;12:70–71.
   Google Scholar
• Wei LJ. Liuwei Dihuang Pill Combined with Caltrate D in treatment of postmenopausal osteoporosis comparative observation. J Pract Tradition Chin Internal Med. 2012;26:54–55.
   Google Scholar
• Ma C. Clinical analysis of Liuwei Dihuang Pill combined with calcium in the treatment of postmenopausal osteoporosis. China Med Pharm. 2011;1:74–75.
   Google Scholar
• Zhang J, Yin SL, Yin HQ, et al. Efficacy observation of Liuwei Dihuang Pill in treating postmenopausal osteoporosis. J Clin Inter Med. 2003;10. 558.
   Google Scholar
• Li WX, Zhang KQ, Liu Z, et al. Effect of Zuogui pill and Yougui pill on osteoporosis: a randomized controlled trial. J Tradit Chin Med. 2018;38:33–42.
   PubMed Web of Science ®Google Scholar
• Sun X. Clinical observation of Jiawei Zuogui Pills in treating osteoporosis low back pain. Chin J Tradition Med Traumatol Orthoped. 2002;05:36–38.
   Google Scholar
• Zou WN, Tian WJ. Clinical observation of Gusongbao capsule in treating osteoporosis. Clin J Med Officers. 2012;40:384.
   Google Scholar
• He X, Shang P, Jiang YF, et al. Clinic effect of Gusongbao capsule in the treatment of osteoporotic vertebral compression fracture. J Liaoning Univ Traditional Chin Med. 2010;12:145–147.
   Google Scholar
• He MR, Yuan CY, Li J. Clinical analysis of 46 cases of osteoporotic spine compression fractures treated with Gusongbao capsule. Nei Mongol J Traditional Chin Med. 2016;35:45.
   Google Scholar
• Higgins JPT, Altman DG, Sterne JAC. Chapter 8: assessing risk of bias in included studies. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration; 2011. Available from www.cochrane-handbook.org
   Google Scholar
• Noh J-Y, Yang Y, Jung H. Molecular mechanisms and emerging therapeutics for osteoporosis. Int J Mol Sci. 2020;21(20):7623.
   PubMed Web of Science ®Google Scholar
• Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005;115(12):3318–3325.
   PubMed Web of Science ®Google Scholar
• Xia WB, Zhang ZL, Lin H, et al. Guidelines for the diagnosis and management of primary osteoporosis (2017). Chin J Osteoporos. 2019;03. 281–309.
   Google Scholar
• Li E, Kong DJ, Yang XH, et al. Effects of kidney-tonifying Chinese medicinal herbs on prevention of rat osteoporosis. Chin J Osteoporos. 2002;02. 73–77.
   Google Scholar
• Zhao YR, Wei X, Jiang JJ, et al. Systemic review of Jintiange capsule in treatment of postmenopausal osteoporosis. Chin J Chin Mater Med. 2019;44:186–192.
   Google Scholar
• Wang QY, Zhang YL, Xie YM. Meta-analysis of total flavonoids from Rhizoma Drynariae (Gusuibu) in treatment of postmenopausal osteoporosis. Chin J Osteoporos. 2019;25:465–471.
   Google Scholar
• Yin H, Wang S, Zhang Y, et al. Zuogui Pill improves the dexamethasone-induced osteoporosis progression in zebrafish larvae. Biomed Pharmacother. 2018;97:995–999.
   PubMed Web of Science ®Google Scholar
• Liu MJ, Li Y, Pan JH, et al. Effects of zuogui pill (see text) on Wnt singal transduction in rats with glucocorticoid-induced osteoporosis. J Tradit Chin Med. 2011;31:98–102.
   PubMed Web of Science ®Google Scholar
• Zhu N, Hou J. Exploring the mechanism of action Xianlingubao prescription in the treatment of osteoporosis by network pharmacology. Comput Biol Chem. 2020;85:107240.
   PubMed Web of Science ®Google Scholar
• Xu F, Gao F. Liuwei Dihuang pill cures postmenopausal osteoporosis with kidney-Yin deficiency: potential therapeutic targets identified based on gene expression profiling. Medicine (Baltimore). 2018;97:e11659.
   PubMed Web of Science ®Google Scholar
• Gong R, Ren S, Chen M, et al. Bioinformatics analysis reveals the altered gene expression of patients with postmenopausal osteoporosis using liuweidihuang pills treatment. Biomed Res Int. 2019;2019:1907906.
   PubMed Web of Science ®Google Scholar
• Ge JR, Xie LH, Chen J, et al. Liuwei Dihuang pill treats postmenopausal osteoporosis with Shen (Kidney) Yin deficiency via janus kinase/signal transducer and activator of transcription signal pathway by up-regulating cardiotrophin-like cytokine factor 1 expression. Chin J Integr Med. 2018;24(6):415–422.
   PubMed Web of Science ®Google Scholar
• Yao ZH, Qin ZF, Cheng H, et al. Simultaneous quantification of multiple representative components in the Xianlinggubao capsule by ultra-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. Molecules. 2017;22:927.
   PubMed Web of Science ®Google Scholar
• Sun J, Yang XG, and Hu YC. Efficacy of Jintiange capsule in the treatment of osteoporosis: a network meta-analysis. Orthop Surg, 2019;11(2):176–186.
   PubMed Web of Science ®Google Scholar
• Wei X, Xu A, Shen H, and Xie Y. (2017). Qianggu capsule for the treatment of primary osteoporosis: evidence from a Chinese patent medicine. BMC Complement Altern Med. 2017;17(1):108.
   PubMedGoogle Scholar
• Zeng XJ, Chen JN, and Jiang HQ, et al. Bayesian network meta-analysis of therapeutic efficacy of Xianlinggubao capsule combined with routine therapy for postmenopausal osteoporosis. China Pharm. 2019;30(18):2556–2562.
   Google Scholar
• An YF, Zhang YL, Xie YM, et al. The effectiveness of Xianlinggubao capsule in the treatment of postmenopausal osteoporosis: a systematic review and meta-analysis. Chin J Osteoporos. 2019;25. 47–61.
   Google Scholar
• Zhao YJ, HU J, Chen J, et al. A systematic evaluation on Xianlinggubao capsule for postmenopausal osteoporosis. Tianjin J Traditional Chin Med. 2010;27:279–282.
   Google Scholar